MOTS-c UK legal status
MOTS-c is one of the headline ‘longevity peptides’ in the consumer market. It is not a licensed UK medicine and the human evidence base is far smaller than the marketing suggests.
Current UK regulatory framing
MOTS-c (Mitochondrial ORF of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. It has attracted research interest for its proposed roles in metabolic regulation, insulin-sensitivity signalling, and exercise physiology.
There is no UK marketing authorisation for MOTS-c. It is not a licensed medicine, food supplement, or cosmetic. The regulatory pathway has not been pursued by any major pharmaceutical developer in the UK.
The evidence base
MOTS-c has a developing preclinical literature in animal models for metabolic and exercise-performance outcomes. Human clinical evidence is early-stage; large RCTs of MOTS-c administration in humans are lacking.
The frequent marketing framing — “mitochondrial repair”, “cellular age reversal”, “reset metabolism” — is downstream of preclinical hypotheses rather than human-trial outcomes.
Sport
As a non-approved substance, MOTS-c falls within S0 of the WADA Prohibited List. Strict liability applies. There is no TUE pathway for using a non-approved peptide for general health or longevity purposes.
What this means in practice
For sellers
Marketing MOTS-c with claims about ageing, mitochondrial repair, or metabolic correction in humans engages the medicinal-product definition. The MHRA can act on this.
For clinics
A UK clinic offering “MOTS-c therapy” for longevity is offering an unlicensed substance for a human-health purpose. The regulatory and clinical-governance questions follow.
For consumers
Unlicensed-substance safety risks (sterility, identity, purity) apply. There is no licensed-medicine framework if something goes wrong.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“MOTS-c reverses cellular ageing”
Marketing claim well ahead of the human evidence. Engages the medicinal-product definition.
“Mitochondrial-repair therapy at our anti-ageing clinic”
Unlicensed substance presented as a treatment. Clinical-governance question about what licensed medicine the prescriber is taking responsibility for.
“Research-grade MOTS-c — for laboratory use only”
Disclaimer doesn't displace the regulatory analysis when sold with dosing instructions to consumers.
“Reset your metabolism in 8 weeks”
Specific timeline outcome claim for an unlicensed compound — engages CAP code on misleading advertising as well.
Sources & further reading
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- WADA Prohibited List — wada-ama.org
Frequently asked questions
- Is MOTS-c legal in the UK?
- MOTS-c is not a licensed UK medicine. Supplying it as a medicine, or with medicinal claims, is unlawful under the Human Medicines Regulations 2012.
- Is MOTS-c prohibited in sport?
- As a non-approved substance MOTS-c falls under S0 of the WADA Prohibited List. Strict liability applies.
- What is MOTS-c actually?
- A 16-amino-acid peptide encoded within mitochondrial DNA. It has been studied preclinically for effects on insulin sensitivity, metabolic regulation, and exercise tolerance. Human data is early-stage.
- Can a UK clinic prescribe MOTS-c?
- There is no UK marketing authorisation for MOTS-c. A clinic offering it as an anti-ageing or metabolic therapy is presenting an unlicensed substance as a medicine.
- Is the anti-ageing claim supported?
- Preclinical research is interesting; human longevity outcomes are not demonstrated. Marketing language that promises ‘mitochondrial repair’ or ‘cellular rejuvenation’ exceeds what the evidence supports.